BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare CNS Disease Analysis: Multiple Sclerosis (MS)

October 07, 2021

A large selection of disease-modifying therapies (DMTs) are currently available in the MS market with a sizable range of attributes, potencies, and safety profiles. Consequently, this set of DMTs typically can yield some relief from this chronic condition. 

Utilization of first-generation DMTs such as Avonex, Betaseron, Copaxone, and Rebif is declining due to their comparatively poor safety, efficacy, and administration profiles versus newer DMTs. Most are genericized, but still see some use in the first-line treatment setting, particularly for less severe cases of MS and especially where payer pressure is involved. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Multiple Sclerosis (MS)
Back to the top Back to the top